Insmed, Inc.(INSM)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Snapshot
$103.95
52-Week Range
$90.39 – $212.75
YTD
-41.31%
IV Rank (30D)
58.91
Straddle Price
$11.25
P/C Vol Ratio
0.36
Market Cap
$22.6B
Fair Value
-17.0% vs price
Confidence: 41% Alpha Score: 0.12

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.50%
Beta vs SPY1.00
Cost of Equity (CAPM)10.00% (VRP-adj)
WACC9.51%
Volatility Risk Premium+30.5pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+30.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.10 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.9B
Return on Equity (TTM)-167.9%
Book / Price3.3%
Gross Margin (TTM)81.8%
FCF Margin (TTM)-110.2%
Debt / Equity0.80
Quality Score2/6 — normal (10y DCF)
SMA 50$115.19 (Market Anchor value)
SMA 20 / Bollinger Mid$100.18
Bollinger Width / SMA2018.7% (drives anchor stability)
Net Debt$-0.0B
Market Cap$21B
Peers used for multiples: AMGN, BIIB, GILD, MRNA, NTRA, REGN, RVMD, VRTX
Blended Fair Value
$85.78
Current Price
$103.38
Deviation
-17.0%
Forward-Return Rank SHORT gates ✓
?
Horizon Expected α z Pred Blended z Rank % Active?
21d -3.8% -0.19 -0.59 62.1%
42d -5.6% -0.11 -0.59 62.1%
63d -6.4% -0.13 -0.59 62.1%
Expected α = forward-return point estimate vs SPY (e.g., +7.5% means the predictor expects this stock to outperform SPY by 7.5% over that horizon). For SHORT direction the model uses a different ranking metric (conviction-weighted deviation, not the LGBM prediction); Expected α is shown for reference. flags rows where Expected α disagrees with the FV direction — two independent signals are in conflict; conviction is low even if rank looks extreme.
Forward-Return Rank. A proprietary ensemble of a machine-learning forward-return model and a conviction-weighted fundamental score, ranked cross-sectionally each day across the S&P 500 (and broader universes on the screener). Each stock is scored at three horizons (21/42/63 trading days). "Active" = top/bottom 5% AND all risk filters pass. Backtested mean alpha vs SPY on active picks: 21d LONG +13.4%, 63d +34.9% (S&P 500, walk-forward). Past performance is not indicative of future results.
Value vs momentum conflict ⚠. The "FV direction" (long/short) comes from the fundamentals-based engine — price vs intrinsic value. The "Expected α" comes from a separate machine-learning predictor trained on ~12 features (sector, options-implied move, beta, institutional flow, etc.). Sometimes the two disagree: a stock is overvalued by fundamentals but the predictor expects it to keep outperforming (sector or momentum tailwinds). When all 3 horizons disagree, treat the direction signal as low-conviction — neither model is strongly recommending a position.
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 21.5× · 5 peers
Peer EV/EBITDA n/a 0% median 15.0× · 5 peers
Peer P/B $22.19 16% median 6.4× · 8 peers
Peer P/S $23.13 16% median 5.2× · 7 peers
Market Anchor (SMA50) $115.19 68% stability 84% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-06-26 · updated 2026-06-26 20:59:30.580000
Info
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834)
Exchange
XNAS
Market Cap
$22.6B

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, prote…

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan +4.52% 23
Feb +6.65% 23
Mar -4.61% 23
Apr +4.95% 23
May +1.26% 23
Jun +2.09% 23
Jul +2.45% 22
Aug -3.93% 22
Sep +10.25% 23
Oct -0.91% 23
Nov +8.73% 23
Dec -1.22% 23
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators
SMA 20: $99.93
SMA 50: $114.32
SMA 200: $152.52
Current: $103.38
EMA 12: $100.93
EMA 26: $104.14
MACD: -3.2108 | Signal: 1.9724
BEARISH
ADX (14): 36.86
TREND
+DI: 17.38
−DI: 21.10
Momentum Oscillators
RSI (14): 48.42
NEUTRAL
Stoch %K: 77.76
Stoch %D: 76.01
Williams %R: -26.82
Volume & Volatility
BB Upper: $108.69
BB Lower: $91.18
NEUTRAL
OBV: 67,837,972
Vol SMA 20: 5,186,365
Vol ROC: 22.42%
ATR: $5.57
True Range: $5.55
HV 20: 60.7%
HV 30: 54.4%
HV 60: 74.5%

Data Summary
Data Points: 500
Last Updated: 2026-06-26T21:15:10.102000
Date Range: 2024-06-28T00:00:00 – 2026-06-26T00:00:00
AI Analysis

Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

Earnings History
5 of 7 under expected move
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-08-08 Pre-Market 8.38% 1.16% 0.14x Within
2024-10-31 Pre-Market 9.32% 4.26% 0.46x Within
2025-05-08 Pre-Market 9.78% 3.19% 0.33x Within
2025-08-07 Pre-Market 10.83% 1.19% 0.11x Within
2025-10-30 Pre-Market 10.99% 16.81% 1.53x Exceeded
2026-02-19 Pre-Market 7.65% 4.38% 0.57x Within
2026-05-07 Pre-Market 12.40% 23.41% 1.89x Exceeded
Options Activity
IV Rank (30D)
58.91
IV Rank (7D)
58.91
Avg IV
93.8%
Straddle (30D)
$11.25
Straddle (7D)
$11.25
P/C Volume
0.36
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
pts EXTREME
ATM — / Wing —
30 DTE / 10d
pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
0.57
Correlation (SPY)
13.7%
0.02
Ann. Volatility
52.2%
SPY Volatility
12.5%

Low volatility - stock moves less than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
Diluted shares outstanding: 203,885,750 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

677 filers215,655,508 shares$33.90B value105.77% of float
# Filer Shares Value % of Total % of Float Period
1 JPMORGAN CHASE & CO Custodian 24,150,499 $3.70B 10.92% 11.85% 2026-03-31
2 VANGUARD GROUP INC Custodian 21,076,344 $3.67B 10.82% 10.34% 2025-12-31
3 BlackRock, Inc. Custodian 16,678,146 $2.73B 8.04% 8.18% 2026-03-31
4 Darwin Global Management, Ltd. 16,805,184 $2.58B 7.60% 8.24% 2026-03-31
5 FMR LLC Custodian 13,160,167 $2.15B 6.35% 6.45% 2026-03-31
6 BAKER BROS. ADVISORS LP 7,421,111 $1.21B 3.58% 3.64% 2026-03-31
7 Artisan Partners Limited Partnership 6,527,301 $1.07B 3.15% 3.20% 2026-03-31
8 D. E. Shaw & Co., Inc. Custodian 5,625,825 $919.93M 2.71% 2.76% 2026-03-31
9 Capital International Investors 5,595,194 $914.89M 2.70% 2.74% 2026-03-31
10 STATE STREET CORP 5,551,699 $907.81M 2.68% 2.72% 2026-03-31
11 RTW INVESTMENTS, LP 4,842,880 $791.91M 2.34% 2.38% 2026-03-31
12 GEODE CAPITAL MANAGEMENT, LLC Custodian 4,450,389 $733.32M 2.16% 2.18% 2026-03-31
13 AMERIPRISE FINANCIAL INC Custodian 3,057,718 $500.00M 1.47% 1.50% 2026-03-31
14 FRANKLIN RESOURCES INC Custodian 2,617,251 $427.97M 1.26% 1.28% 2026-03-31
15 CITADEL ADVISORS LLC Custodian 2,182,571 $356.89M 1.05% 1.07% 2026-03-31
16 Invesco Ltd. Custodian 1,988,968 $325.24M 0.96% 0.98% 2026-03-31
17 Orbis Allan Gray Ltd 1,872,824 $306.24M 0.90% 0.92% 2026-03-31
18 UBS Group AG Custodian 1,737,481 $284.11M 0.84% 0.85% 2026-03-31
19 MORGAN STANLEY Custodian 1,631,906 $284.02M 0.84% 0.80% 2025-12-31
20 BANK OF AMERICA CORP /DE/ Custodian 1,502,281 $245.65M 0.72% 0.74% 2026-03-31
21 Integral Health Asset Management, LLC 1,500,000 $245.28M 0.72% 0.74% 2026-03-31
22 WESTFIELD CAPITAL MANAGEMENT CO LP 1,468,459 $240.12M 0.71% 0.72% 2026-03-31
23 SEI INVESTMENTS CO Custodian 1,395,794 $228.24M 0.67% 0.68% 2026-03-31
24 Capital World Investors 1,362,291 $222.74M 0.66% 0.67% 2026-03-31
25 NORTHERN TRUST CORP Custodian 1,294,000 $211.59M 0.62% 0.63% 2026-03-31
26 filers$359.32M notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $80.99M 22.54% 2026-03-31
2 CITADEL ADVISORS LLC Custodian $62.09M 17.28% 2026-03-31
3 JANE STREET GROUP, LLC Custodian $54.70M 15.22% 2026-03-31
4 CITIGROUP INC Custodian $32.70M 9.10% 2026-03-31
5 Squarepoint Ops LLC $22.61M 6.29% 2026-03-31
6 MILLENNIUM MANAGEMENT LLC Custodian $22.45M 6.25% 2026-03-31
7 JPMORGAN CHASE & CO Custodian $16.10M 4.48% 2026-03-31
8 Eversept Partners, LP $15.37M 4.28% 2026-03-31
9 Caption Management, LLC $7.06M 1.97% 2026-03-31
10 WOLVERINE TRADING, LLC Custodian $6.32M 1.76% 2025-09-30
11 NOMURA HOLDINGS INC $4.91M 1.37% 2026-03-31
12 CAPITAL FUND MANAGEMENT S.A. $4.50M 1.25% 2026-03-31
13 TUDOR INVESTMENT CORP ET AL $4.02M 1.12% 2026-03-31
14 Walleye Capital LLC $3.78M 1.05% 2026-03-31
15 IMC-Chicago, LLC Custodian $3.73M 1.04% 2026-03-31
16 SIMPLEX TRADING, LLC Custodian $3.06M 0.85% 2026-03-31
17 GROUP ONE TRADING LLC Custodian $2.80M 0.78% 2026-03-31
18 Walleye Trading LLC $2.32M 0.65% 2026-03-31
19 Point72 Asset Management, L.P. $2.21M 0.61% 2026-03-31
20 Tidal Investments LLC $2.06M 0.57% 2026-03-31
21 D. E. Shaw & Co., Inc. Custodian $1.86M 0.52% 2026-03-31
22 BALYASNY ASSET MANAGEMENT L.P. $1.78M 0.50% 2026-03-31
23 Alphadyne Asset Management LP $1.05M 0.29% 2026-03-31
24 HAP TRADING, LLC $618.32K 0.17% 2025-09-30
25 Cubist Systematic Strategies, LLC $230.42K 0.06% 2025-09-30
24 filers$239.11M notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $67.04M 28.04% 2026-03-31
2 Artia Global Partners LP $45.74M 19.13% 2026-03-31
3 JANE STREET GROUP, LLC Custodian $17.94M 7.50% 2026-03-31
4 Caption Management, LLC $16.40M 6.86% 2026-03-31
5 Jefferies Financial Group Inc. $16.34M 6.83% 2026-03-31
6 Parallax Volatility Advisers, L.P. $14.42M 6.03% 2026-03-31
7 683 Capital Management, LLC $9.81M 4.10% 2026-03-31
8 CITADEL ADVISORS LLC Custodian $8.31M 3.47% 2026-03-31
9 NOMURA HOLDINGS INC $8.18M 3.42% 2026-03-31
10 WOLVERINE TRADING, LLC Custodian $6.97M 2.91% 2025-09-30
11 Walleye Capital LLC $4.38M 1.83% 2026-03-31
12 Point72 Asset Management, L.P. $4.10M 1.72% 2026-03-31
13 Centiva Capital, LP $4.09M 1.71% 2026-03-31
14 IMC-Chicago, LLC Custodian $3.70M 1.55% 2026-03-31
15 CAPITAL FUND MANAGEMENT S.A. $3.34M 1.40% 2026-03-31
16 PEAK6 LLC $2.31M 0.96% 2026-03-31
17 Squarepoint Ops LLC $1.41M 0.59% 2026-03-31
18 TUDOR INVESTMENT CORP ET AL $1.19M 0.50% 2026-03-31
19 D. E. Shaw & Co., Inc. Custodian $899.36K 0.38% 2026-03-31
20 Alphadyne Asset Management LP $719.49K 0.30% 2026-03-31
21 SIMPLEX TRADING, LLC Custodian $605.02K 0.25% 2026-03-31
22 Walleye Trading LLC $572.32K 0.24% 2026-03-31
23 GROUP ONE TRADING LLC Custodian $441.50K 0.18% 2026-03-31
24 Cubist Systematic Strategies, LLC $216.01K 0.09% 2025-09-30
Insider Activity
Latest: 2026-06-24
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-06-24 Michael Alexander Smith Chief Legal Officer Sell (S) −1,806 $95.82 -$173.1K EDGAR
2026-06-24 Samuele Butera SVP, GM, Global Respiratory Award (A) +7,342 EDGAR
2026-06-10 William Lewis Chair and CEO Sell (S) −6,515 $94.03 -$612.6K EDGAR
2026-06-05 Martina M.D. Flammer Chief Medical Officer Sell (S) −4,424 $102.90 -$455.2K EDGAR
2026-06-05 William Lewis Chair and CEO Sell (S) −7,605 $102.27 -$777.8K EDGAR
2026-06-05 Michael Alexander Smith Chief Legal Officer Sell (S) −2,159 $102.27 -$220.8K EDGAR
2026-06-05 Sara Bonstein Chief Financial Officer Sell (S) −2,404 $102.27 -$245.9K EDGAR
2026-06-05 Roger Adsett Chief Operating Officer Sell (S) −2,370 $102.27 -$242.4K EDGAR
2026-05-22 Michael Alexander Smith Chief Legal Officer Sell (S) −6,149 $108.47 -$667.0K EDGAR
2026-05-20 William Lewis Chair and CEO Mixed −14,865 $82.32 -$2.45M EDGAR
2026-05-15 William Lewis Chair and CEO Sell (S) −13,283 $116.18 -$1.54M EDGAR
2026-05-15 LEO LEE Director Award (A) +3,305 EDGAR
2026-05-15 Clarissa Desjardins Director Award (A) +3,305 EDGAR
2026-05-15 David R Brennan Director Award (A) +3,305 EDGAR
2026-05-15 MELVIN MD SHAROKY Director Award (A) +3,305 EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
38 insiders · @ $103.38
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 GEOFFREY ALLAN President, CEO and Chairman 1,826,682 $188.84M $118.0K 3 2009-04-02
2 KEVIN P TULLY Executive VP & CFO 597,290 $61.75M $34.2K 5 2011-12-23
3 William Lewis Chair and CEO 492,841 $50.95M -$115.62M 91 2026-06-10
4 Stephen C. Glover President Follow-on Biologics 477,162 $49.33M $62.9K 3 2009-04-02
5 STEINAR J ENGELSEN Director 320,802 $33.16M $834.3K 24 2021-11-03
6 Doug Farrar Vice President, ITP 292,055 $30.19M $0 2 2009-04-02
7 MELVIN MD SHAROKY Director 252,928 $26.15M -$7.64M 52 2026-05-15
8 GRAHAM K CROOKE Director 228,404 $23.61M $8.4K 6 2010-06-11
9 KENNETH G CONDON Director 168,504 $17.42M $0 5 2010-06-11
10 Dennis M Lanfear Director 168,404 $17.41M $0 5 2010-06-11
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Notice of Proposed Sale (Form 144)
Latest: 2026-06-25
Last 30d: 9 filings · $4.9M notice value  ·  Last 90d: 23 filings · $37.6M notice value · 5 unique filers · 57% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.

Source & freshness: Parsed directly from EDGAR primary-doc XML. Daily refresh; new filings typically appear here the morning after they hit EDGAR.

Top 90-day filers: Roger Adsett (3, $15.4M) · William Lewis (8, $12.6M) · Michael Smith (5, $4.5M) · Martina Flammer (5, $3.9M) · Sara Bonstein (2, $1.2M)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-06-25 William Lewis Officer 21,398 $2.21M 2026-06-25 Merrill Lynch 10b5-1 EDGAR
2026-06-22 Michael Smith Officer 1,806 $173.0K 2026-06-22 Merrill Lynch 10b5-1 EDGAR
2026-06-08 William Lewis Officer 6,515 $612.6K 2026-06-08 Merrill Lynch 10b5-1 EDGAR
2026-06-05 Martina Flammer Officer 1,858 $192.8K 2026-06-05 Merrill Lynch 10b5-1 EDGAR
2026-06-03 Sara Bonstein Officer 2,404 $245.9K 2026-06-03 Merrill Lynch EDGAR
2026-06-03 Martina Flammer Officer 2,566 $262.4K 2026-06-03 Merrill Lynch EDGAR
2026-06-03 Roger Adsett Officer 2,370 $242.4K 2026-06-03 Merrill Lynch EDGAR
2026-06-03 Michael Smith Officer 2,159 $220.8K 2026-06-03 Merrill Lynch EDGAR
2026-06-03 William Lewis Officer 7,605 $777.8K 2026-06-03 Merrill Lynch EDGAR
2026-05-22 Michael Smith Officer 6,149 $667.0K 2026-05-22 Merrill Lynch 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
Recent SEC Filings
Latest: 2026-05-15
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Accession Link
2026-05-15 0001140361-26-021648 EDGAR
2026-05-07 0001140361-26-019430 EDGAR
2026-04-07 0001140361-26-013659 EDGAR
2026-03-23 0001140361-26-010651 EDGAR
2026-02-19 0001140361-26-006116 EDGAR
2026-01-09 0001140361-26-000778 EDGAR
2025-12-17 0001140361-25-045836 EDGAR
2025-11-18 0001140361-25-042598 EDGAR
2025-10-30 0001140361-25-039789 EDGAR
2025-08-12 0001140361-25-030537 EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
2026-02-19 0001104506-26-000009 EDGAR
2025-02-20 0001104506-25-000009 EDGAR
2024-02-22 0001104506-24-000008 EDGAR
2023-02-23 0001104506-23-000009 EDGAR
2022-02-17 0001104506-22-000008 EDGAR
2021-02-25 0001104506-21-000005 EDGAR
2020-02-25 0001104506-20-000007 EDGAR
2019-02-22 0001104506-19-000009 EDGAR
2018-02-23 0001104506-18-000002 EDGAR
2017-02-23 0001047469-17-000856 EDGAR
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-05-07 0001104506-26-000032 EDGAR
2025-10-30 0001104506-25-000053 EDGAR
2025-08-07 0001104506-25-000043 EDGAR
2025-05-08 0001104506-25-000026 EDGAR
2024-10-31 0001104506-24-000033 EDGAR
2024-08-08 0001104506-24-000026 EDGAR
2024-05-09 0001104506-24-000016 EDGAR
2023-10-26 0001104506-23-000025 EDGAR
2023-08-03 0001104506-23-000018 EDGAR
2023-05-04 0001104506-23-000012 EDGAR
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio32.1
P/S Ratio27.6
EV/EBITDA-19.9
TTM Revenue$0.8B
TTM Net Income$-1.2B
TTM EPS$-5.74
ROE-167.9%
Debt/Equity0.80